|
業務類別
|
Biotechnology |
|
業務概覽
|
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-relatedepilepsy. |
| 公司地址
| 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731 |
| 電話號碼
| +1 512 501-2444 |
| 傳真號碼
| +1 512 501-0414 |
| 公司網頁
| https://www.filanatx.com |
| 員工數量
| 20 |
| Mr. Richard J. Barry |
President, Chief Executive Officer and Director |
美元 675.00K |
28/04/2026 |
| Mr. R. Christopher Cook |
Chief Operating and Legal Officer |
美元 463.98K |
28/04/2026 |
| Mr. Eric J. Schoen |
Chief Financial Officer and Principal Accounting Officer |
美元 475.00K |
28/04/2026 |
|
|
| Dr. Claude Nicaise,M.D. |
Chairman of the Board |
28/04/2026 |
| Mr. Richard J. Barry |
President, Chief Executive Officer and Director |
28/04/2026 |
| Dr. Patrick J. Scannon,M.D.,PhD |
Independent Director |
28/04/2026 |
| Ms. Dawn Carter Bir |
Independent Director |
28/04/2026 |
| Mr. Pierre Gravier |
Independent Director |
28/04/2026 |
| Mr. Michael J. O'Donnell, Esq. |
Independent Director |
28/04/2026 |
| Dr. Robert Z. Gussin, PhD |
Independent Director |
28/04/2026 |
| Mr. Robert Anderson, Jr |
Independent Director |
28/04/2026 |
|
|
|
|
